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The RNA polymerase I system for in vivo synthesis of recombinant influenza vRNA molecules was used for the expression
of a chimeric protein, consisting of the 341-amino-acid ectodomain of the glycoprotein E2 of classical swine fever virus and
the 37-amino-acid C-terminal membrane anchor of the influenza virus hemagglutinin (HA). During infection with an influenza
A helper virus the amplified pseudo-viral RNA was packaged into progeny virions together with influenza vRNA segments.
The foreign fusion protein E2-HA was shown to be physically incorporated into the viral envelope. Incorporation of a third
major glycoprotein into the envelope did not affect biological functions of HA and neuraminidase that are required for the
generation of infectious virus particles. Based on mutational analyses of the cytoplasmic tail of E2-HA fusion proteins three
modes of interaction during virus budding have been observed: nonspecific low-level incorporation (truncated tails), specific
full-level incorporation (wild-type amino acid sequence or minor variations of it), and exclusion from incorporation (elongated
tails). © 1998 Academic Press
INTRODUCTION
Influenza A viruses are negative-strand RNA viruses
with a segmented genome that consists of eight viral
RNA (vRNA) segments. It has been shown that all the
control functions for promoting synthesis, polyadenyla-
tion, and packaging of influenza vRNAs reside within the
23 59-terminal and the 16 39-terminal nucleotides, which
also are almost identical among all eight vRNA segments
(Lamb and Krug, 1996; Flick et al., 1996). Pseudo-viral
RNAs have been constructed using various influenza
recombinant cDNA techniques (Luytjes et al., 1989; Zobel
et al., 1993; Mena et al., 1996) by inserting foreign gene
sequences between those terminal vRNA elements and
were shown to be propagated and packaged into prog-
eny virions (Enami et al., 1991; Neumann et al., 1994).
As a rule foreign individual RNA segments are lost
after a few passages, because their gene products are
not essential for influenza virus propagation. Bicistronic
influenza virus RNA segments have been constructed
either with two open reading frames separated by an
internal ribosomal entry site (IRES; Garcı´a-Sastre et al.,
1994) or connected to each other via a protease recog-
nition sequence that is cleaved posttranslationally by an
ubiquitous cellular protease, such as the P2A element
obtained from foot-and-mouth disease virus (Percy et al.,
1994). In each case these bicistronic constructs consist
of a regular viral gene plus a foreign gene connected to
it. However, mutational analysis of the influenza viral
promoter has shown that promoter variants with higher
expression levels than wild-type support the expression
of foreign proteins from additional vRNA segments for
more than six passages without the need for any selec-
tion system (Neumann and Hobom, 1995). Expression
rates of foreign proteins in this system may be modu-
lated by the choice among several such promoter vari-
ants (Flick et al., 1996).
The influenza A virus envelope contains two major
glycoproteins, hemagglutinin (HA) and neuraminidase
(NA), and in addition the much less abundant M2 protein
(Lamb and Krug, 1996). All three envelope proteins con-
sist of an ectodomain, a transmembrane segment (26,
29, or 19 hydrophobic amino acids), and an internal
cytoplasmic domain (11, 6, or 54 amino acids in length).
All three surface proteins HA, NA, and M2 are trans-
ported to the plasma membrane along the exocytotic
pathway, while the inner structural proteins reach their
destination across the cytoplasm. Like many other en-
veloped viruses, influenza A viruses assemble in specific
areas of the plasma membrane where the viral glyco-
proteins will form patches. Cellular glycoproteins are
mostly excluded from these viral assembly sites (Lamb
and Krug, 1996).
The HA cytoplasmic sequence is highly conserved
among 13 HA subtypes (Nobusawa et al., 1991) and
might be exposed in a specific conformation due to two
conserved cysteine residues (and a third one nearby in
the transmembrane region) that have been shown to be
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palmitylated to a large extent (Naeve and Williams, 1990;
Veit et al., 1991). However, various alterations of the
cytoplasmic domain including substitutions of the two
cysteine residues and even deletion of the entire tail
sequence have failed so far to reveal defined biological
functions of the cytoplasmic tail. HA regular cytoplasmic
sequences are not required for HA biosynthesis and
intracellular transport to the plasma membrane (Doyle et
al., 1985), for receptor binding and membrane fusion
(Naim and Roth, 1993), or for assembly into virus parti-
cles (Jin et al., 1994, 1996). On the other hand the hem-
agglutinin cytoplasmic tail has been shown to stimulate
the membrane association of protein M1 (Enami and
Enami, 1996), and short synthetic peptides with the HA
cytoplasmic sequence inhibited virus assembly (Collier
et al., 1991). In a number of other viruses a specific
interaction between cytoplasmic tail sequences and the
underlying matrix proteins has been demonstrated, as
for Semliki Forest virus and Sindbis virus (Gaedigk-
Nitschko and Schlesinger, 1991), vesicular stomatitis vi-
rus (Whitt et al., 1989), or parainfluenza virus 3 (Yao and
Compans, 1995). Cytoplasmic tail sequence elements
are frequently involved in intracellular targeting through
interaction with cellular factors (Thomas and Roth, 1994;
Fiedler et al., 1996; Nishimura and Balch, 1997).
Here we report the expression by an influenza virus
vector of the foreign viral glycoprotein E2 of classical
swine fever virus (CSFV), its transport to the plasma
membrane, and incorporation of that full-size glycopro-
tein into the envelope of infectious influenza virus parti-
cles. This differs from the normal situation, since during
CSFV propagation the E2 protein is found associated
only with intracytoplasmic membranes where the CSFV
virions assemble (Thiel et al., 1996). Full-level incorpora-
tion of E2 into influenza virions was achieved by fusion of
the E2 ectodomain with the complete influenza HA trans-
membrane and cytoplasmic domain, while incorporation
of constructs with a truncated tail or with altered trans-
membrane segments was reduced by a factor of 3 to 5.
RESULTS
Generation of recombinant influenza viruses
Plasmid constructs were designed according to the
reverse genetic approach for in vivo expression of influ-
enza vRNAs mediated by murine RNA polymerase I
(Neumann et al., 1994). cDNA sequences coding for the
E2-HA protein and its derivatives were inserted between
the noncoding regions in the influenza vRNA pro-
moter-up mutant pHL1104 (G3A , U5C, C8U at the vRNA
39 end) (Neumann and Hobom, 1995). The E2-HA fusion
protein (pHL1959) and the mutants derived from it were
synthesized as outlined under Materials and Methods.
The amino acid sequences of the transmembrane and
cytoplasmic domains of the various fusion proteins that
were used in the experiments described below are doc-
umented in able 1. The DNA constructs were transfected
as a group into subconfluent B82 cells (at 4–8% yields).
After 6 h the cells were infected with helper virus influ-
enza A/FPV/Bratislava at an m.o.i. of 4. The supernatant
was harvested at 8 h p. i. and passaged on MDCK cells
without applying any selective pressure. Progeny virus
therefore consisted of a mixture of recombinant and
wild-type influenza A virus, the majority of the latter
originating from those cells that were infected, but not
transfected. The fraction of recombinant viruses in-
creases from one step of passage to the next due to an
enhanced amplification rate of the recombinant vRNA
segment carrying the promoter-up variant (Neumann and
Hobom, 1995).
Expression of chimeric E2-HA in infected MDCK cells
For immunofluorescent staining MDCK cells that were
infected with recombinant FPV/E2, FPV/E2-HA, or wild-
type FPV were fixed with acetone/methanol to allow
staining of intracellular proteins. The cells were incu-
bated with a monoclonal antibody specific for CSFV E2 or
for influenza H7 HA. After incubation with a secondary
FITC-labeled antibody, cells infected with recombinant
FPV/E2 or with FPV/E2-HA showed bright fluorescence
(Figs. 1B and 1D). Recombinant E2 protein was found in
a mostly perinuclear localization, similar to the pattern
observed in CSFV-infected cells (Ko¨nig et al., 1995). The
fluorescence of E2-HA expressing cells resembles that
of helper virus infected cells stained with an anti-H7 HA
monoclonal antibody (Fig. 1F).
Intracellular proteins and proteins on the cell surface
of transfected and infected MDCK cells were differenti-
ated by treatment with 2% paraformaldehyde before
staining with monoclonal antibody a18. Only traces of the
E2 antigen were found on the surface of nonpermeabi-
lized cells infected with FPV/E2 (Fig. 1A), whereas FPV/
E2-HA-infected cells showed bright fluorescence, indi-
cating that E2-HA was efficiently transported to the cell
surface (Fig. 1C), in this regard equivalent to influenza-
infected cells that had been immunostained with an
anti-H7 HA monoclonal antibody (Fig. 1E). A second
monoclonal antibody (F48) recognizing another, confor-
mational, epitope of the E2 protein also resulted in im-
munostaining of cells infected with recombinant FPV/E2
or FPV/E2-HA, indicating that folding of at least one
antigenic domain of the recombinant E2 protein was
correct (data not shown).
In order to demonstrate that the influenza transmem-
brane region plus cytoplasmic domain was sufficient to
trigger the surface expression of the fusion protein a
copy of the E2-HA construct was inserted into a eukary-
otic pCMV expression vector. Figure 1G shows the immu-
nofluorescent labeling of nonpermeabilized cells ex-
pressing E2-HA in the absence of influenza virus infec-
tion, demonstrating that no interaction with influenza
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viral proteins is necessary to get E2-HA transported to
the cell surface.
After the localization of recombinant proteins E2 and
E2-HA in the infected cells had been studied by immu-
nofluorescent staining we analyzed the size of E2-HA in
Western blots and compared it with the size of E2 in
CSFV. MDCK cells were infected with wild-type FPV or
with FPV/E2-HA recombinant virus (in mixed prepara-
tions). Cell lysates were prepared at 8 h postinfection
and separated on PAA gels together with purified CSFV
as a control. After transfer of the polypeptides to immu-
noblot membranes incubation with anti-E2 monoclonal
antibody a18 resulted in staining of a single 52-kDa
protein band in the lanes displaying recombinant E2-HA
(Fig. 2A, lane 3) or CSFV (lane 2). No degradation prod-
ucts were detected in any of the preparations indicating
that transport along the exocytic pathway did not affect
the intracellular stability of E2-HA.
Incorporation of E2-HA in the influenza A viral
envelope
Our finding that recombinant E2-HA was transported
to the cell surface suggested that it might also be incor-
porated into infectious virus particles. Wild-type and re-
combinant virions were purified by sucrose density gra-
dient centrifugation and analyzed by PAGE and Western
blot with monoclonal antibody a18. Figure 2B clearly
shows that E2-HA can be demonstrated in purified re-
combinant virions. The difference between the estimated
molecular weights of influenza E2-HA (52 kDa) and bac-
ulovirus-expressed CSFV E2 (55 kDa) appears to be in
accordance with their different transmembrane and cy-
toplasmic regions (100 amino acids versus 37) and only
partial glycosylation in insect cells. Although the influ-
enza virus proteins HA1, NP, and NA have molecular
weights similar to recombinant E2-HA no protein band
could be detected in the FPV-negative control, indicating
that staining with the monoclonal antibody a18 is highly
specific for E2. In sucrose density gradients the E2-HA
chimeric protein was found predominantly in the peak
fractions which have the highest influenza protein con-
centration and hemagglutination activity (Fig. 3), sug-
gesting that E2-HA was incorporated in influenza virus
particles as a structural component.
The morphology of orthomyxovirus preparations varies
between spherical and filamentous particles depending on
TABLE 1
RNA Polymerase I/Influenza Expression Constructs for Cytoplasmic Tail and Transmembrane Region Variants of CSFV-E2/HA Fusion Proteins
Note. Amino acid sequences in single-letter code are indicated in standard format for HA-derived segments and in italics for E2-derived segments;
deviations due to site-directed mutagenesis are in bold print. Only the first and last two amino acids of the E2 ectodomain precursor sequence are
indicated; sequence gaps are marked by dashes. TM, transmembrane domain; CT, cytoplasmic domain; 39, influenza nontranslated 39-end; 59,
influenza nontranslated 59-end; tl, murine polymerase-I terminator; pI, murine polymerase-I promoter.
a For examples of surface immunofluorescence see Figs. 1A, 1C, 1E.
b For E2 virion envelope incorporation data as observed by Western blot see Fig. 5.
c RNA polymerase II expression construct cloned in vector pcDNA3.
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FIG. 1. Presence of E2 and E2-HA in MDCK cells infected with recombinant influenza A virus. MDCK cells were inoculated (A, B) with FPV/E2
(obtained from pHL2000), or (C, D) with FPV/E2-HA (obtained from pHL1959), or (E, F) with FPV helper virus. After 6–7 h the cells were permeabilized
with acetone:methanol for total cell protein staining (B, D, F) or with 2% paraformaldehyde for surface staining (A, C, E). In addition, noninfected B82
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the influenza strain and passage history. Since no recom-
binant influenza viruses have been constructed previously
that contain an additional, foreign polypeptide of similar
size in their lipid envelopes it was investigated whether the
presence of a third structural surface protein would alter
influenza virus morphology. Virus particles that had been
purified by sucrose gradient centrifugation were incubated
with monospecific anti-E2 hyperimmune serum plus a gold-
labeled secondary antibody and analyzed by electron mi-
croscopy (Fig. 4). Immunogold labeling using monoclonal
antibody a18 was similarly observed, albeit to a lower
extent than with the monospecific serum (not shown). No
selection against wild-type virions had been applied, and
the immunogold labeling technique showed that in this
second passage supernatant 16% of the virions were re-
combinant particles. The high density of gold particles sur-
rounding individual recombinant virus particles demon-
strates an extensive incorporation of E2-HA. All virus parti-
cles analyzed were spherical in shape and apart from the
presence of E2-HA in the virus envelope, no difference
could be detected in the morphology of recombinant and
nonrecombinant particles.
Mutational analysis of the transmembrane and
cytoplasmic domain of E2-HA
For the design of recombinant proteins expressed by
influenza virus vectors it would be a desirable feature if the
cytoplasmic tail would be accessible to protein engineer-
ing. The cytoplasmic domain sequence is highly conserved
among 13 subtypes of influenza HA, with 5 amino acid
residues of 11 being strictly identical (Nobusawa et al.,
1991). The biological importance of the influenza HA cyto-
plasmic tail has not been clearly defined. Therefore, struc-
tural requirements and restrictions for the incorporation of a
foreign protein in the influenza virus lipid membrane has
been studied by mutational analysis of the cytoplasmic
domain of recombinant E2-HA.
Influenza virions containing mutagenized E2-HA pro-
teins were rescued from cell cultures that had been
transfected with 5 mg plasmid DNA. Immunofluorescent
labeling of cells expressing mutagenized E2-HA was
performed to detect alterations of intracellular transport,
and progeny virus from tissue culture supernatant was
purified by adsorption to and elution from chicken red
blood cells. This method resulted in a 10-fold viral con-
centration. Aliquots of the purified virions were analyzed
by Western blot. The results for all the mutants analyzed
are included in Table 1(right column).
A first group of mutants was constructed to study serial
truncations of the HA cytoplasmic domain. Figure 5 shows
that E2-HA mutants with 2 to 5 residual amino acids
(pHL1999, pHL2194, pHL2193, pHL2192) are incorporated
into virus particles at 33 to 37% (6 6%) the rate of incorpo-
ration of the E2-HA construct containing the 11-residue
full-size cytoplasmic tail (pHL1959). Exchange of the 2
amino acids immediately adjacent to the transmembrane
domain for 2 other charged amino acids (pHL2062:
QR3KQ) did not further reduce the rate of incorporation.
Constructs with an exact duplication of the HA cyto-
plasmic tail (pHL2190) were transported to the cell sur-
face at normal rates, but they were completely excluded
from virus particles (Fig. 5). Because the sequence of
these constructs contains no alterations of the wild-type
sequence the fusion protein (pHL2190) is probably ex-
cluded by steric hindrance. The same result was ob-
tained for constructs where 6 amino acids of 11
cells expressing E2-HA from a pcmv expression vector (pHL2288) were treated with 2% paraformaldehyde at 24 h posttransfection for surface
immunofluorescence staining (G). E2 antigen was detected with monoclonal antibody a18 specific for CSFV E2 and anti-mouse IgG labeled with FITC
as a secondary antibody. H7 HA was stained with an anti-H7 HA monoclonal antibody (I13). E2 and E2-HA were both efficiently expressed by influenza
virus vectors (B, D), but only E2-HA shows surface fluorescence (C), whereas E2 appears to be retained in the cell (A). E2-HA expressed from a pCMV
expression vector (G) is transported to the cell surface in the absence of influenza viral proteins.
FIG. 2. Immunoblot analysis of recombinant E2-HA. (A) Expression of
E2-HA in infected cell lysates. Cell lysates were prepared at 8 h p. i. from
infected MDCK cells and separated on 12.5% SDS–PAA gels. The molecular
weight of the protein markers is indicated on the left margin. The cells had
been infected with recombinant FPV/E2-HA virus as obtained after pHL1959
DNA transfection and helper virus infection (lane 3). Pelleted CSFV (lane 2)
and cell lysate from cells infected with nonrecombinant FPV (lane 4) were
included as positive and negative controls. Polypeptides were transferred to
immunoblot membranes and incubated with monoclonal antibody a18 spe-
cific for CSFV E2. Absence of E2-specific bands with molecular weights less
than the 52-kDa fusion protein in lane 3 indicates that modification of the
C-terminus and transport along the exocytotic pathway did not decrease the
intracellular stability of E2-HA. (B) Incorporation of E2-HA in influenza virions.
Recombinant and wild-type influenza virions were purified through 15 to 60%
continuous sucrose gradients and analyzed in Western blots as described
above. Specific protein bands with a molecular weight of 55 and 52 kDa were
detected in lanes 2 (baculovirus-CSFV E2) and 3 (FPV/E2-HA), but not in lane
4 (nonrecombinant FPV). The results demonstrate that E2-HA expressed by
recombinant influenza vectors is incorporated in infectious virus particles as a
structural component.
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(pHL2255) amino acids or 6 of 8 (pHL2298) amino acids
had been replaced by histidine.
The influenza virus HA is acylated through thioester
linkages at three highly conserved cysteine residues
located in the cytoplasmic domain and at the carboxy
terminal end of the transmembrane region (Veit et al.,
1991). However, both of these do not appear to be nec-
essary for intracellular transport or membrane anchoring
of the recombinant E2-HA protein (pHL1997 and
pHL1998). Fusion proteins with C3S mutations in either
position were incorporated with the same efficiency as
the unmodified E2-HA control (Table 1). Therefore, we
conclude that substitution of either of these two cysteine
residues for serine in the E2-HA cytoplasmic domain will
support full-level (specific) incorporation, while fusion
proteins with truncated tails of five amino acids or less
will support only low-level (nonspecific) incorporation.
A point mutation (V3A) at position 18 of the HA trans-
membrane sequence (resulting from the insertion of a
restriction site in the DNA sequence) did not change the
incorporation rate substantially (pHL2189). Even con-
structs with further substitutions of foreign hydrophobic
amino acids in the membrane spanning domain, con-
nected with an influenza cytoplasmic segment of 11 (or 2)
amino acids (pHL2124; pHL2069) were still incorporated
into the purified virions, at 23 6 6% of full level. The
exchanged hydrophobic parts of these constructs were
derived from the E2 transmembrane sequence with an
R3V substitution at amino acid 14 of the E2 hydrophobic
C-terminus. A protein consisting of the E2 ectodomain
plus an original hydrophobic E2 anchor (containing argi-
nine), which was fused to 14 C-terminal amino acids of
influenza HA (pHL2000) was, however, retained in the
cell. The wild-type CSFV E2 transmembrane domain has
the potential to span the membrane twice, with its central
arginine residue exposed at the cytoplasmic side of the
membrane. In this conformation the attached HA cyto-
plasmic tail might be located together with the ectodo-
main at the interior of the transport vesicles, and no
transport to the surface or virion incorporation was ob-
served for this construct.
DISCUSSION
Recombinant influenza virus vectors constitute a ver-
satile system for expression and delivery of heterologous
proteins both in the cytoplasm and, as is shown here, in
the virion envelope as well. In this contribution we report
the incorporation of full-size foreign glycoprotein E2 of
CSFV into the influenza virion as a structural component
FIG. 3. Analysis of recombinant FPV/E2-HA virus sucrose gradient fractions. Recombinant influenza FPV/E2-HA virus was pelleted from tissue
culture supernatant and sedimented through a 15 to 60% continuous sucrose gradient. Fractions (0.5 ml) were harvested from the top of the gradient.
Aliquots of each fraction were assayed for protein concentration and HA titer. A 2-ml aliquot of each gradient fraction was analyzed in immunoblots
with monoclonal antibody a18 specific for CSFV E2 and with a monospecific antiserum against the M1 protein of influenza virus N. E2-HA and
influenza M1 proteins were observed predominantly in gradient fractions with the highest protein concentration and HA activity.
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together with its genetic incorporation as a ninth vRNA
segment. The cDNA sequence coding for an E2-HA fu-
sion protein was inserted between the 59 and 39 terminal
sequences of influenza vRNA, which were further con-
nected to RNA polymerase I promoter and terminator
elements. The E2 protein ectodomain was fused with the
C-terminal 37 amino acids of the influenza HA transmem-
brane and cytoplasmic domain. Pseudo-viral RNAs were
synthesized from transfected plasmid DNA by RNA poly-
merase I in influenza virus-infected cells and packaged
among the viral progeny vRNAs into virus particles. The
gene product E2-HA was expressed at the cell surface
and incorporated into the envelope of recombinant viral
particles, which are present in a mixture with helper
viruses originating from infected, but not also DNA-trans-
fected, cells.
Recombinant pseudo-viral RNAs are frequently lost
after only a few passages, because their gene products
are not essential for virus propagation. However, if
equipped with a mutagenized influenza vRNA promoter
sequence (Neumann and Hobom 1995; Flick et al., 1996),
the increased activity of those promoter-up variants is
able to compensate for the accidental loss of the non-
essential vRNA segment, or even increase its concen-
tration among the population of viral progeny, to 16% after
two passages (Fig.4) and more further on. One of our
balanced CSFV E2 promoter constructs has been pas-
saged 11 times without significant variation in the frac-
tion of recombinant viruses or concentration of recombi-
nant protein (Y.Z. and G.H., unpublished).
During CSFV replication all the viral proteins are trans-
lated from a single ORF as a large polyprotein that is
processed co- and posttranslationally by viral and cellu-
lar proteases. During virus replication the surface glyco-
protein E2 of CSFV is found predominantly at intracyto-
plasmic membranes and only in traces at the plasma
FIG. 4. Immunoelectron microscopy of purified influenza FPV/E2-HA
virions. Recombinant influenza FPV/E2-HA or wild-type FPV virus was
purified in a 15 to 60% continuous sucrose gradient. Immunogold
labeling was performed using the on-grid method with monospecific
antiserum raised against recombinant CSFV E2 protein and goat anti-
rabbit IgG (labeled with 5-nm gold particles) as a secondary antibody.
Recombinant particles can be distinguished among nonrecombinant
particles by their labeling with anti-E2 mAb. All the virions analyzed
were spherical, with an estimated diameter of 120 nm. Apart from the
presence of the recombinant E2 antigen on the viral surface no differ-
ence in morphology could be detected between recombinant and
nonrecombinant influenza virions. In the second passage virus prepa-
ration analyzed 16% of the virus particles were recombinant particles.
The bar marker indicates 100 nm.
FIG. 5. Site-directed mutagenesis of the influenza HA cytoplasmic
domain in E2-HA chimeric proteins. The respective plasmid DNAs (see
Table 1) have been cotransfected into B82 cells together with a GFP
expression plasmid, and transfection yields were determined in aver-
age at 5.15% (individually at 4.9/5.1/5.2/4.6/5.3/5.9%; in the order of lanes
2 to 7) in a single experiment (and similarly in other such experiments),
based on GFP fluorescence. Tissue culture supernatants from MDCK
cells infected at second passage with recombinant influenza FPV/
E2-HA containing viral progeny were purified by adsorption to and
elution from chicken red blood cells. Aliquots of these 10-fold concen-
trated preparations were electrophoretically separated in 12% SDS–
PAA gels and transferred to immunoblot membranes. Lanes: 1, molec-
ular weight markers; 2, FPV/E2-HA (pHL1959: QRGNIRCNICI); 3, FPV/
E2-HA (pHL2192: QR); 4, FPV/E2-HA (pHL2193: QRG); 5, FPV/E2-HA
(pHL2194: QRGN); 6, FPV/E2-HA (pHL1999: QRGNI); 7, FPV/E2-HA
(pHL2190: QRGNIRCNICIQRGNIRCNICI). Viral proteins were detected
with monoclonal antibody a18 specific for CSFV E2 or with monospe-
cific antiserum raised against the M1 protein of influenza A virus N. At
constant amounts of M1 protein for the different virus preparations, the
rate of incorporation of E2-HA constructs with cytoplasmic domains
truncated down to five amino acids or fewer (lanes 3–6) was found to
be reduced to 33 to 37% (66% in average in parallel experiments)
compared to the reference construct (lane 2) containing the unmodified
HA cytoplasmic tail. A construct containing an exact duplication of the
cytoplasmic tail (lane 7) was completely excluded from virions.
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membrane. CSFV assembly occurs within the infected
cell at intracytoplasmic membranes, and the mature vi-
rus particles are released from membrane vesicles most
likely by exocytosis (Stark et al., 1993; Rice, 1996; Thiel et
al., 1996). Recombinant E2 expressed from an influenza
virus vector is similarly transported to the cell surface
only in traces (Fig.1A). Equivalent results have been ob-
tained previously with vaccinia virus-expressed E2
(Ko¨nig et al., 1995). In contrast E2-HA was efficiently
transported to the cell surface and the cellular distribu-
tion patterns of E2-HA and influenza HA were found to be
equivalent in infected cells. An E2-HA construct that was
expressed in noninfected cells demonstrates that this
redirection is independent of viral proteins.
CSFV E2 is anchored in the ER membrane by a trans-
membrane domain that is divided by a single charged
arginine residue at position 13 of a 24-amino-acid hydro-
phobic sequence. The bipartite transmembrane domain
has the potential to span the ER membrane twice and
appears to be responsible for the retention of E2 (pHL2044),
or of fusion proteins containing the E2 transmembrane
region (pHL2000), in intracytoplasmic membranes. Fusion
proteins containing in essence a single amino acid change
(arginine to valine) at position 13 of the CSFV transmem-
brane sequence plus an HA cytoplasmic tail of 11 or only 2
amino acids (pHL2124, pHL2069) were transported to the
plasma membrane and found incorporated into influenza
virions. Detectable amounts of a fusion protein (pHL2124)
containing a transmembrane segment of foreign sequence
in connection with a foreign ectodomain were observed in
influenza virus particles, which indicates that incorporation
of glycoproteins does not require a specific interaction of
the ectodomain or of the transmembrane region with other
viral components.
A series of variations analyzed in the HA cytoplasmic do-
main sequence may be summarized as follows: (1) Cytoplas-
mic tails that were too large in size, including the duplicated
wild-type cytoplasmic sequence, or that were too different
in conformation (substitutions by His6 sequences) lead to
complete exclusion of the membrane protein even if the
sequence was below 11 amino acids in size (pHL2298).
This mechanism may contribute to the efficient exclusion of
various host glycoproteins and even a partial exclusion of
influenza virus M2 protein with its tail of 54 amino acids
from budding virions (Zebedee and Lamb, 1988). (2) Trun-
cated cytoplasmic tails that were created by a stepwise
deletion or other short tails with foreign charged residues in
close proximity to the transmembrane region still allowed
incorporation of the respective membrane protein, although
at a level reduced by a factor of 3 (Table 1). This low-level,
nonspecific or ‘‘passive’’ incorporation of short tail variants
appears not to be influenced by specific interaction of the
remaining sequence with matrix protein M1, since all dele-
tion variants truncated to five amino acids or fewer were
incorporated to the same extent (Fig. 5). This indirectly
argues for a specific interaction, possibly between M1 and
a full-size C-terminal tail sequence, to achieve full-level
incorporation. In our system the recombinant protein—
without selection pressure—has to compete during as-
sembly with original HA from helper virus, and the effect of
a reduced interaction with M1 may be more pronounced
than in other systems. Single cysteine to serine substitu-
tions eliminating fatty acid attachment sites at positions 7 or
10 of the cytoplasmic tail sequence did not reduce the
incorporation levels. Therefore, the amino acid residue(s) in
the C-terminal half of the cytoplasmic tail sequence that are
involved in what might be called an ‘‘active’’ recognition for
incorporation remain to be determined.
Recently, a similar two-step mode of incorporating
foreign glycoproteins into a viral envelope has been
observed for VSV (Kretzschmar et al., 1997). The model of
a two-step incorporation mechanism may offer a com-
promise between several published mutational analyses
of the HA cytoplasmic tail region (Naim and Roth, 1993;
Enami and Enami, 1996; Jin et al., 1996) but it remains in
conflict with a few others (Zurcher et al., 1994). Similarly
a partial impairment upon truncation of the NA cytoplas-
mic tail has been observed recently (Garcı´a-Sastre and
Palese, 1995; Mitnaul et al., 1996).
The structure and function(s) of E2 during the CSFV
replication cycle are not known in detail. The majority of
E2 forms heterodimers with E1, another CSFV glycopro-
tein (Weiland et al., 1990), although in addition ho-
modimers have also been detected. The quarternary
structure of CSFV E2 in influenza virus envelopes has not
been studied; however, HA-like trimerization appears
unlikely. Although assays are not yet available for bio-
logical functions of E2, binding of an anti-E2 monoclonal
antibody that recognizes a conformational epitope sug-
gests an at least partially correct conformation.
We provide evidence for the incorporation of a foreign
protein in influenza virions without detectable interfer-
ence with influenza virus replication. The method de-
scribed here may be more widely applicable for con-
structing infectious recombinant influenza viruses with
foreign glycoproteins and other proteins incorporated
into their envelopes.
One possible application of recombinant influenza vi-
ruses carrying in their envelope foreign viral glycopro-
teins such as CSFV E2 is their use for dual vaccine
purposes, either as an inactivated or as a live attenuated
vaccine. Recombinant influenza viruses expressing a
foreign epitope as part of their HA or NA proteins have
been shown to elicit B- and T-cell responses to those
epitopes (Castrucci et al., 1992; Li et al., 1992, 1993;
Muster et al., 1994, 1995). However, the immune re-
sponse to a single epitope is not generally sufficient to
induce protective immunity, and the number of proteins
for which epitopes have been clearly defined is rather
limited. Also, the majority of neutralizing epitopes is
conformational rather than linear, and insertion of
epitopes into foreign viral proteins may alter their con-
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formation and hence immunogenicity and stability. Incor-
poration of the entire ectodomain of a foreign protein in
natural or near-natural conformation mimics more
closely the antigenic structure of the foreign protein in
the donor virus. Experiments to explore the immune
response against influenza viruses carrying the E2-HA
protein are in progress.
MATERIALS AND METHODS
Virus strains and cell lines
Influenza A/FPV/Bratislava (H7N7) was grown in the
allantoic cavity of embryonated chicken eggs. B82
mouse fibroblast cells (McDougall et al., 1980) were
used for transfection and gene rescue experiments. Re-
combinant influenza A/FPV/Bratislava was propagated in
Madin–Darby canine kidney (MDCK) cells. All cell lines
were grown in Dulbecco’s modified Eagle’s Medium
(DMEM) supplemented with 10% fetal calf serum and
antibiotics.
Antibodies
Monoclonal antibodies a18 and F48 (anti-CSFV E2)
and 24/16 (anti-CSFV Erns) have been characterized pre-
viously (Weiland et al., 1990, 1992). Monospecific serum
was prepared in rabbits using purified recombinant
CSFV E2 expressed in the baculovirus system; IgG was
prepared using protein A–Sepharose according to stan-
dard laboratory techniques (Lengsfeld, unpublished).
Virus purification
Virus was sedimented from infected tissue culture su-
pernatant in a Beckman SW28 rotor at 25,000 rpm for 60
min. The resuspended virus pellet was layered on top of a
continuous 15 to 60% sucrose gradient and centrifuged for
2 h at 35,000 rpm in a Beckman SW41 rotor. The virus band
was collected, pelleted, and resuspended in 300 ml TSE (20
mM Tris, 150 mM NaCl, 2 mM Na2EDTA, pH 7.8). For some
experiments gradients were fractionated in 500-ml aliquots
and the fractions stored at 270°C.
For virus purification by adsorption to and elution from
chicken red blood cells, tissue culture supernatant from
infected cells was clarified by low-speed centrifugation.
Freshly prepared packed chicken red blood cells were
added to a final concentration of 2%. After 60 min ad-
sorption on ice the red blood cells were washed twice
with ice-cold PBS. Virus was eluted in 1/10 vol PBS for 60
min at 37°C. Finally, the red blood cells were removed by
low-speed centrifugation.
Construction of CSFV E2-HA (plasmid pHL1959)
Basic constructs for the intracellular expression of
pseudo-viral RNA segments from a murine polymerase-I
promoter and terminator cassette have been described
previously (Zobel et al., 1993; Neumann and Hobom,
1995). All constructs described in this report originate
from plasmid pHL1104 (influenza virus vRNA promoter
triple mutant: 39- G3A, T5C, C8T). Their gene products
are expressed at levels above wild-type promoter rates.
All constructs contain the flanking nontranslated regions
of influenza RNA segment 4 (HA) with several nucleotide
substitutions to introduce restriction sites close to both
ends of the coding sequence.
The E2 coding sequence for the leader peptide and
ectodomain was obtained from a cDNA construct
(pHCK9) of CSFV strain Alfort-Tu¨bingen by PCR amplifi-
cation using sense and antisense primers 59-AAA-
ATCGCGATCATGAAAGCATCGAGAGGACA and 59- ACT-
ACCGCGGGATCCACTCGGCAAAGTAG (first and last
codons of the E2 sequence underlined: 223M substi-
tuted for 223I; 341E). The PCR fragment was digested
with restriction endonucleases BamHI and NruI and
cloned into pHL1732, an HA (H3 Victoria) carrying deriv-
ative of pHL1104. Upon deletion of the major part of the
HA sequence (cleavage by BamHI and NruI), only the
C-terminal 37-amino-acid transmembrane and cytoplas-
mic domain sequences remained in the fusion construct
(see plasmid map of pHL1959 in Table 1). After confirm-
ing the external regions of the fusion cDNA construct by
sequencing, the central region of the PCR-derived E2
fragment was exchanged for an authentic cDNA se-
quence, within the boundaries of NheI and ApaI, at
CSFV-2434 and 3251, respectively. As a result of this
strategy a unique BamHI restriction site is situated at the
boundary of the E2 and HA coding regions, while an
artificially inserted XbaI site is located at the stop codon,
to facilitate variations of the tail sequence as well as
exchanges of ectodomain segments. The resulting CSFV
E2-HA fusion protein contains a 23-amino-acid signal
peptide (derived from the proximal transmembrane se-
quence of the viral polyprotein) and extends over 364
codons from positions 2362 to 3454 of the CSFV se-
quence (Meyers et al., 1989), with conversion of 2364 ATA
(223 Ile) to initiator ATG (223 Met) and GAGT.GGATC-
CTG (Glu-Trp-Ile-Leu) constituting the E2-HA sequence
across the fusion point.
Mutagenesis of the influenza cytoplasmic tail
sequence
A first series of fusion proteins with variations in the
cytoplasmic tail was constructed by inserting short PCR
fragments covering the HA portion between the unique
BamHI and XbaI restriction sites. Together with encoded
variations designed for the amino acid tail sequences
several restriction sites (SnaBI, Eco47III, SphI, SspI,
AsuII, NsiI) were introduced via oligonucleotide se-
quences into that terminal region without resulting in
additional amino acid variations (except for an L to A
exchange within the transmembrane sequence for some
of the constructs). In a second round further variations
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were introduced by inserting short duplex oligonucleo-
tides, e.g., between SphI and NsiI. All HA tail variations
have been confirmed by sequencing across the entire
tail area. HA tail mutants constructed by insertion of
oligonucleotides include two cysteine to serine substitu-
tions (pHL1997, pHL1998), a stepwise series of truncated
variants that were constructed by introducing stop
codons at the respective positions (pHL1999, pHL2194,
pHL2193, pHL2192), as well as His6 substitutions
(pHL2255, pHL2298) and a duplication of the entire 11-
amino-acid tail sequence (pHL2190).
Another round of sequence variation concerned the
transmembrane region, which was entirely or partially
converted into the transmembrane region of CSFV E2 by
PCR amplification and exchange of the corresponding
part of the HA transmembrane sequence. Primers were
used which provide the respective cleavage sites for
insertion into the CSFV E2 sequence, e. g., in pHL2000 a
short PCR fragment of CSFV E2 sequence flanked by
Sau3A and SphI ends was inserted between the BamHI
and SphI sites of the HA construct, which are located
near the left and right borders of the HA transmembrane
sequence. Included in the program was also an influenza
vector construct expressing the wild-type CSFV E2 pro-
tein with its own original tail segment (pHL2044). The
basic E2-HA fusion construct as present in pHL1959 was
also inserted in its entire length into a pCMV expression
vector (pcDNA3; Invitrogen Inc.) via its flanking NruI and
XbaI restriction sites, fused into the EcoRV and XbaI sites
that are present in the multiple cloning region of pcDNA3
(pHL2288).
Transfection and preparation of recombinant
influenza viruses
Plasmids were transfected into subconfluent B82 cells
as described previously (Flick et al., 1996). For a quanti-
tative determination of B82 transfection yields (4–8%) we
used cotransfection with a second plasmid expressing
by the pCMV promoter a green fluorescent protein variant
(GFP; Chalfie et al., 1994; Siemering et al., 1996). At 6 h
posttransfection the B82 monolayers were washed twice
with PBS and infected with influenza A/Bratislava at an
m.o.i. of 4. After 8 (or up to 16) h of incubation at 37°C the
supernatant was harvested and passaged on MDCK
monolayers.
Western blot analysis
MDCK cells that were infected with recombinant influ-
enza viruses were harvested 8 h postinfection with a rubber
policeman. The cell pellet was lysed in 100 ml Laemmli gel
loading buffer. Cell lysate (5 ml) or 1 ml of purified wild-type
influenza virus or 2 ml of purified recombinant influenza
virus was separated on a 12.5 % polyacrylamide gel under
reducing conditions. Proteins were transferred to a nitro-
cellulose membrane and incubated with a monoclonal an-
tibody specific for E2. Anti-mouse IgG-biotinylated whole
antibody from sheep was used as a secondary antibody.
After incubation with streptavidin-conjugated horseradish
peroxidase (HRP), the color reaction was carried out by
adding 10 ml PBS, 2 ml 4-chloro-1-naphtol (0.3% in metha-
nol), and 20 ml H2O2.
Immunofluorescent staining of infected cells
MDCK cells that were 90% confluent were infected
with undiluted recombinant influenza virus. At 6–7 h cells
were washed twice with warm PBS and once with cold
PBS. For detection of intracellular antigens the cells were
fixed and permeabilized with acetone/methanol (1/1)
(v/v) for 20 min at 220°C. For detection of surface anti-
gens the cells were fixed with 2% paraformaldehyde in
PBS for 20 min at 4°C. The fixed cells were incubated for
16 h with an E2-specific monoclonal antibody (a18 or
F48) at 4°C or at room temperature for 1 h. Cells were
washed three times with PBS and immunofluorescent
staining was performed subsequently with FITC-conju-
gated goat anti-mouse IgG. After 30 min incubation at
37°C the cells were washed with PBS, mounted with
buffered glycerol, and examined under the fluorescence
microscope.
Immunoelectron microscopy
Suspensions containing pHL1959 E2-HA recombinant
FPV together with FPV helper virus, or only influenza A/FPV/
Bratislava helper virus, were immunogold-stained using the
on-grid method: 400-mesh Formvar- and carbon-coated,
glow-discharged copper rhodium grids were floated on
droplets of diluted virus suspensions for 10 min. Subse-
quently, nonspecific binding sites were saturated by plac-
ing the grids on droplets of 0.5% (w/v) BSA (Fluka, Neu-Ulm)
in PBS (3 3 5 min). Incubation with the first antibody (rabbit
anti-CSFV E2 IgG, 1:400, or mAb a18 anti-CSFV E2, 1:10;
both diluted in PBS/0.5% BSA) was performed for 60 min at
room temperature in a humid chamber. After five washing
steps on droplets of PBS (5 min each) the grids were
transferred to a droplet of secondary antibody (goat anti-
rabbit IgG 5-nm gold particles or goat anti-mouse IgG
10-nm gold particles, both diluted 1:50 in 0.5% BSA/PBS) for
60 min. Subsequent washing steps were in PBS (three
times for 5 min) and in distilled water (three times for 5 min).
Negative staining was performed using 1% phosphotung-
stic acid (pH 7.4) in PBS for 1 min. Controls included stain-
ing of recombinant virus particles without the first antibody
or with a nonspecific antibody (mAb 24/16 anti-CSFV Erns)
and staining of wild-type virus with rabbit anti-CSFV E2 IgG
as well as mAb a18. Air-dried grids were examined in a
Zeiss EM 902 transmission electron microscope at an in-
strumental magnification of 30,000 or 50,0003. The ratio of
labeled to nonlabeled virus particles was estimated and
micrographs were taken on Kodak SO-163 film.
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